Efforts in redesigning the antileukemic drug 6-thiopurine: decreasing toxic side effects while maintaining efficacy
作者:Arnaldo X. Torres Hernandez、Chamitha J. Weeramange、Prathibha Desman、Anthony Fatino、Olivia Haney、Ryan J. Rafferty
DOI:10.1039/c8md00463c
日期:——
inhibition of UDPGDH while retaining therapeutic efficacy. Three new 6TP analogs bearing a halogen (Br, Cl, and F) at the C8 position have been achieved over five-synthetic steps in overall yields of 16 to 32%. Each of these analogs were shown to have reduced inhibition towards UDPGDH, with Ki values of 192, 163, 215 μM, respectively. In addition, the bromine, chlorine, and fluorine analogs were shown to possess
6-硫嘌呤(6TP)是目前开的处方药,用于治疗从克罗恩氏病到急性淋巴细胞性白血病的各种疾病。尽管其有效的作用方式是通过作为脱氧鸟苷的硫醇模拟物掺入DNA,但其给药具有严重的毒性,这阻碍了潜在的治疗应用。我们以前曾在体外报道,6TP的氧化代谢产物,特别是6-硫尿酸(6TU,K i 7μM )是UDP-葡萄糖脱氢酶(UDPGDH)的有效抑制剂,UDPGDH是负责UDP-形成的酶。葡萄糖醛酸(UDPGA),是肝脏排毒过程中必不可少的底物。一个在体内进行了调查以探究6TU是否抑制了大鼠肝细胞中的UDPGDH,并且观察到6TU确实确实抑制了胆红素与UDPGA的结合。胆红素排泄失败与6TP给药相关的大多数已报道的毒性有关。努力构建在C8位取代的6TP类似物,以减少对UDPGDH的抑制,同时保持治疗功效。通过五个合成步骤,已经获得了三个新的6TP类似物,它们在C8位置带有卤素(Br,Cl和F),总产率为